How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Exclusive: Campaign group calls on institutional shareholders to vote against re-election of bosses overseeing net zero row-back Bank chairs who water down their lenders’ climate commitments this year ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...
Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...
SAN FRANCISCO -- One new startup is called Recursive with an "e." Another is called Ricursive with an "i." They are trying to do the same thing: Build artificial intelligence that can improve itself ...
Hosted on MSN
A very scared Trump is backtracking | Opinion
Days after the brutal execution of 37-year-old Alex Pretti in Minneapolis, we still don’t know the identities of the masked ICE agents who shot him dead. They fled the scene and are nowhere to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results